More research news from ACR/ARP 2019

The first phase III trial of anifrolumab has failed to show a significant overall benefit for patients with systemic lupus erythematosus when taken in addition to standard care, but does demonstrate some clinical response improvements that the researchers say deserve further investigation.

Findings from the HOPE trial indicate that short-term treatment with prednisolone may provide pain relief for patients with hand osteoarthritis experiencing a flare following withdrawal of NSAIDs.

A pooled analysis of data from the SELECT trials suggests that the selective JAK1 inhibitor upadacitinib is not associated with an increased risk for major adverse cardiovascular events or venous thromboembolism among patients with rheumatoid arthritis.

Study results contradict suggestions that the routine use of ultrasound to target imaging remission in early rheumatoid arthritis provides additional benefit over achieving clinical remission.

Patients with ANCA-associated vasculitis who receive maintenance therapy with rituximab are more likely to remain in remission than those given azathioprine, according to the results of the RITAZAREM trial.